Radiopharm Theranostics Limited (RADX)

Radiopharm Theranostics Limited is a clinical-stage biotechnology company based in Melbourne, Australia, that develops radiopharmaceuticals for diagnosing and treating cancer. Its shares are listed on the Australian Securities Exchange, and its American Depositary Shares trade on the Nasdaq Stock Market under the ticker RADX.

Radiopharmaceuticals pair a targeting molecule, such as an antibody, peptide or small molecule, with a radioactive isotope, allowing the same target to be used for imaging and for delivering radiation directly to tumor cells. This combined approach is known as theranostics.

Radiopharm has assembled its pipeline largely by licensing technologies from universities and research institutions, including programs directed at targets such as PD-L1, HER2, B7-H3 and TROP2, with potential uses in solid tumors including breast, lung, brain and other cancers.